Della Porta et al. reported similar findings where mutations in TP53 as well as ASXL1 and RUNX1 were independent risk factors for poor OS in patients with MDS or secondary AML (N = 401) who received allo-HCT [63]. This evidence concerns the gene TP53 and acute myeloid leukemia.